Why semaglutide is titrated slowly (and why you shouldn't rush it)
Every semaglutide FDA label prescribes a gradual dose-escalation schedule for one main reason: to reduce the risk of gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, and constipation. The Ozempic, Wegovy, and Rybelsus labels each state that the starting dose exists specifically to ease the body into the drug, not to treat the condition.
This is why the lowest doses are explicitly labeled as ineffective on their own. The Ozempic 0.25 mg starting dose and the Rybelsus 3 mg starting dose are both described in the prescribing information as initiation doses that are 'not for glycemic control' — they are ramp-up steps, nothing more.
The labels also give prescribers flexibility to slow down. Both the Wegovy and oral-semaglutide labels say that if a patient does not tolerate a dose during escalation, the clinician can delay the next step. That decision belongs to the prescriber, not the patient. Do not increase, decrease, skip, or double a dose on your own.
- The starting dose is a tolerance step, not a therapeutic dose.
- Slower titration is a recognized tool to manage side effects — a prescriber, not the patient, decides to pause.
- Never self-adjust, split, or stack doses to 'catch up' or speed results.
Ozempic dosage (type 2 diabetes): 0.25 → 0.5 → 1 → 2 mg weekly
Per the FDA Ozempic label, treatment starts at 0.25 mg injected subcutaneously once weekly for 4 weeks. After 4 weeks the dose increases to 0.5 mg once weekly, which is the first dose intended to affect blood sugar.
If additional glycemic control is needed, the label allows an increase to 1 mg once weekly after at least 4 weeks on 0.5 mg, and then to 2 mg once weekly after at least 4 weeks on 1 mg. The recommended maintenance dosage is 0.5 mg, 1 mg, or 2 mg based on glycemic control, and the maximum recommended dosage is 2 mg once weekly.
Ozempic is FDA-approved for type 2 diabetes and for reducing cardiovascular and kidney risk in specific adults with type 2 diabetes — not for weight loss. Any weight-management use is a clinical decision made off-label by a prescriber. Ozempic is administered on the same day each week, at any time of day, with or without meals.
- Start: 0.25 mg weekly × 4 weeks (initiation only).
- Step up: to 0.5 mg, then 1 mg, then 2 mg, each after ≥4 weeks.
- Maximum: 2 mg once weekly.
- Source: FDA Ozempic prescribing information (2025).
Wegovy injection dosage (weight & cardiovascular): four steps to 2.4 mg
The FDA Wegovy label uses a five-dose escalation: 0.25 mg for weeks 1–4, 0.5 mg for weeks 5–8, 1 mg for weeks 9–12, 1.7 mg for weeks 13–16, and then 2.4 mg once weekly as the maintenance dose from week 17 onward. That is roughly 16 weeks to reach the target dose.
The recommended maintenance dosage for weight reduction and cardiovascular risk reduction is 2.4 mg once weekly, or 1.7 mg once weekly if 2.4 mg is not tolerated. For the metabolic dysfunction-associated steatohepatitis (MASH) indication added in 2025, the maintenance dose is 2.4 mg weekly, dropping to 1.7 mg if not tolerated.
If a patient does not tolerate an escalation dose, the label instructs the prescriber to consider delaying the increase — again, a clinician's call. Wegovy is injected subcutaneously in the abdomen, thigh, or upper arm, once weekly on the same day each week.
- Weeks 1–4: 0.25 mg → Weeks 5–8: 0.5 mg → Weeks 9–12: 1 mg → Weeks 13–16: 1.7 mg → Maintenance: 2.4 mg.
- Maintenance is 2.4 mg (recommended) or 1.7 mg weekly.
- Source: FDA Wegovy prescribing information, updated 08/2025.
The Wegovy 7.2 mg high dose (Wegovy HD), added in 2026
In March 2026 the FDA approved a higher-dose Wegovy — a 7.2 mg once-weekly injection marketed as Wegovy HD — for reducing excess body weight and maintaining weight loss long-term in adults with obesity. It is now the highest labeled semaglutide injection dose.
The label is specific about sequencing: the dose may be increased to a maximum of 7.2 mg once weekly only for patients who have tolerated the 2.4 mg dose for at least 4 weeks and for whom additional weight reduction is clinically indicated. It is not a starting dose and not a step everyone takes.
The 7.2 mg pen delivers the higher dose in a single injection. Whether to move from 2.4 mg to 7.2 mg is a decision a prescriber makes based on response and tolerability — not something a patient initiates.
- 7.2 mg weekly is the maximum labeled Wegovy injection dose (Wegovy HD).
- Only after tolerating 2.4 mg for ≥4 weeks, if more weight reduction is clinically indicated.
- Source: FDA press announcement, March 19, 2026; FDA Wegovy label.
Rybelsus dosage (oral semaglutide for diabetes): 3 → 7 → 14 mg daily
Rybelsus is the oral tablet form of semaglutide, FDA-approved for type 2 diabetes. The label starts patients at 3 mg orally once daily for 30 days — a dose it explicitly notes is not effective for glycemic control and exists only for initiation. On day 31 the dose increases to 7 mg once daily.
On day 61 or later, if no additional glycemic control is needed the label says to stay at 7 mg; if more control is needed, the dose can increase to 14 mg once daily, which is the maximum. Oral semaglutide requires far higher milligram numbers than the injections because much less of it is absorbed through the gut.
Rybelsus has strict administration rules that affect whether it works at all: take it on an empty stomach in the morning with no more than 4 ounces of plain water, swallow the tablet whole, and wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Note that Novo Nordisk has also introduced oral Ozempic tablets (1.5 mg, 4 mg, 9 mg strengths) for diabetes; those are a different formulation and are not substitutable milligram-for-milligram with Rybelsus.
- Days 1–30: 3 mg daily (initiation only). Days 31–60: 7 mg. Day 61+: stay at 7 mg or increase to 14 mg.
- Maximum: 14 mg once daily.
- Take on an empty stomach with ≤4 oz water; wait ≥30 minutes before anything else.
- Source: FDA Rybelsus/oral-semaglutide prescribing information (2026).
The oral Wegovy weight-loss pill: 1.5 → 4 → 9 → 25 mg daily
On December 22, 2025, the FDA approved an oral Wegovy tablet — the first oral GLP-1 approved for chronic weight management in adults, distinct from the lower-dose Rybelsus diabetes pill. Novo Nordisk began US rollout in early 2026.
Per the label, the pill starts at 1.5 mg once daily for 30 days and titrates roughly every 30 days through the available strengths (1.5 mg, 4 mg, 9 mg) up to a recommended maintenance dose of 25 mg once daily. If a patient cannot tolerate the 25 mg maintenance dose, the label says to consider switching to the Wegovy 1.7 mg weekly injection. Like Rybelsus, it is taken on an empty stomach in the morning with a small amount of water, swallowed whole, followed by a 30-minute wait.
In clinical trials, the 25 mg oral Wegovy dose produced average weight loss in the range of roughly 13.6% to 16.6% of body weight depending on the trial and analysis, comparable to the 2.4 mg injection in separate (not head-to-head) studies.
- Approved Dec 2025 for weight management; maintenance dose 25 mg once daily.
- Titration: 1.5 → 4 → 9 → 25 mg, about 30 days per step.
- If 25 mg isn't tolerated, the label suggests switching to Wegovy 1.7 mg injection.
- Source: FDA/Novo Nordisk approval, December 2025; Scientific American, Dec 2025.
Compounded semaglutide: no FDA-approved dose
Compounded semaglutide is not an FDA-approved finished drug. Compounded products are mixed by pharmacies and are not reviewed by the FDA for safety, effectiveness, or quality the way Ozempic, Wegovy, and Rybelsus are. There is no FDA titration schedule or approved maintenance dose for compounded semaglutide.
Because dosing, concentration, and even the exact salt form can vary between compounders, the numbers on the FDA brand labels above do not automatically transfer to a compounded product. Some safety concerns and dosing errors have been reported specifically because compounded vials and syringes are not standardized.
If you are considering or using a compounded product, the dose is whatever a licensed prescriber orders for that specific formulation — and that is the only source you should follow. Do not apply a brand-drug schedule to a compounded vial.
- Not FDA-approved as a finished drug; no FDA-standardized dose or titration schedule.
- Concentration and dosing vary by compounder — brand-label numbers don't transfer.
- Follow only the specific prescriber's instructions for the specific product.
How to think about 'the right dose' (this page is a reference, not advice)
The schedules above are what the FDA labels print. They are public reference information, not a personalized plan. The label itself repeatedly hands dosing decisions to the prescriber: whether to escalate, whether to pause, which maintenance dose to settle on, and whether a given patient is even a candidate.
Real-world dosing is affected by side-effect tolerance, other medications, kidney and GI conditions, insurance coverage of specific pens or tablets, and current supply. Only a licensed clinician who knows your medical history can weigh those factors.
glp1zoom is an educational comparison site. We do not prescribe, sell, or manufacture medication, and nothing here is medical advice. Use these schedules to understand the conversation you'll have with a clinician — not to start, stop, or change a dose yourself.
Missed a dose? What each label says
The FDA labels give a specific missed-dose rule, and it differs by product. This is reference information attributed to each label — not personal instructions; a prescriber confirms what to do in your situation, and doubling up to catch up is not advised unless a clinician says so.
- Ozempic (weekly injection): the label says take a missed dose within 5 days; if more than 5 days have passed, skip it and resume the usual weekly schedule
- Wegovy injection (weekly): if the next scheduled dose is more than 2 days (48 hours) away, take the missed dose; if it is less than 2 days away, skip it and resume schedule
- Rybelsus (daily oral tablet): skip the missed tablet and take the next one the following day — do not take two tablets to make up